New pill targets rare gene to shrink tumors in advanced cancers

NCT ID NCT04280081

First seen Apr 25, 2026 · Last updated Jun 19, 2026 · Updated 14 times

Summary

This study tests a daily pill called selpercatinib in people with advanced solid tumors or medullary thyroid cancer that have a specific RET gene change. The goal is to see if the drug can shrink tumors and how safe it is. About 77 participants in China will take the drug, and doctors will measure tumor response using scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130000, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai/China, 200030, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, 200120, China

  • Southern Medical University Nanfang Hospital

    Guangzhou, Guangdong, 510515, China

  • The First Affiated Hospital Of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, Zhejiang, 310003, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310014, China

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma non-small cell lung carcinoma RET fusion positive cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.